Literature DB >> 27656541

Could Topical Minoxidil Cause Non-Arteritic Anterior Ischemic Optic Neuropathy?

Habibullah Aktas1, Sevil Alan2, Elif Betül Türkoglu3, Özge Sevik4.   

Abstract

Minoxidil hair formulation is commonly used for the treatment of male or female androgenic alopecia. Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. The drug is marketed as 2% and 5% topical solutions. This over-the-counter product is considered safe, but should be used with caution. Furthermore, minoxidil is an orally active vasodilator for treatment of severe hypertension. Typical side effects of minoxidil are faster heart rate, augmented heart function and stroke volume (which can be associated with reduced vascular resistance upon baroflex stimulus), retained sodium and water and abnormal hair growth. The most common adverse reactions of the topical formulation are limited to irritant and allergic contact dermatitis on the scalp. Herein, we report a non-arteritic anterior ischemic optic neuropathy caused by topical 5% minoxidil treatment that was resolved after discontinuation of minoxidil.

Entities:  

Keywords:  Androgeneticalopecia; Eye; NAION; Optic nerve

Year:  2016        PMID: 27656541      PMCID: PMC5028441          DOI: 10.7860/JCDR/2016/19679.8250

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

1.  Topical use of minoxidil in children and systemic side effects.

Authors:  S Georgala; A Befon; E Maniatopoulou; C Georgala
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

Review 2.  Treatment of nonarteritic anterior ischemic optic neuropathy.

Authors:  Edward J Atkins; Beau B Bruce; Nancy J Newman; Valérie Biousse
Journal:  Surv Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 6.048

Review 3.  Nonarteritic anterior ischaemic optic neuropathy.

Authors:  Shu Fen Ho; Sushma Dhar-Munshi
Journal:  Curr Opin Ophthalmol       Date:  2008-11       Impact factor: 3.761

4.  Topical minoxidil therapy for androgenic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group.

Authors:  P Karam
Journal:  Int J Dermatol       Date:  1993-10       Impact factor: 2.736

5.  Large pericardial effusion induced by minoxidil.

Authors:  Mehmet Çilingiroğlu; Nuri Akkuş; Salil Sethi; Kalgi A Modi
Journal:  Turk Kardiyol Dern Ars       Date:  2012-04

6.  Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome.

Authors:  Sohan Singh Hayreh; M Bridget Zimmerman
Journal:  Ophthalmology       Date:  2007-08-15       Impact factor: 12.079

Review 7.  Minoxidil.

Authors:  S L Linas; A S Nies
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

8.  Management of ischemic optic neuropathies.

Authors:  Sohan Singh Hayreh
Journal:  Indian J Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 1.848

9.  Clinical use of minoxidil (Loniten).

Authors:  A M Joekes; F D Thompson; P F O'Regan
Journal:  J R Soc Med       Date:  1981-04       Impact factor: 18.000

10.  A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions.

Authors:  Mahesh N Belhekar; Santosh R Taur; Renuka P Munshi
Journal:  Indian J Pharmacol       Date:  2014 Jan-Feb       Impact factor: 1.200

  10 in total
  4 in total

Review 1.  Low-level laser therapy for the treatment of androgenic alopecia: a review.

Authors:  Evan Darwin; Alexandra Heyes; Penelope A Hirt; Tongyu Cao Wikramanayake; Joaquin J Jimenez
Journal:  Lasers Med Sci       Date:  2017-12-21       Impact factor: 3.161

2.  Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice.

Authors:  Ramya Lakshmi Rajendran; Prakash Gangadaran; Soon Sun Bak; Ji Min Oh; Senthilkumar Kalimuthu; Ho Won Lee; Se Hwan Baek; Liya Zhu; Young Kwan Sung; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

3.  Overexpression of Nanog in amniotic fluid-derived mesenchymal stem cells accelerates dermal papilla cell activity and promotes hair follicle regeneration.

Authors:  Junghyun Park; Eun Kyoung Jun; Daryeon Son; Wonjun Hong; Jihoon Jang; Wonjin Yun; Byung Sun Yoon; Gwonhwa Song; In Yong Kim; Seungkwon You
Journal:  Exp Mol Med       Date:  2019-07-04       Impact factor: 8.718

4.  Macrophage-Derived Extracellular Vesicle Promotes Hair Growth.

Authors:  Ramya Lakshmi Rajendran; Prakash Gangadaran; Chang Hoon Seo; Mi Hee Kwack; Ji Min Oh; Ho Won Lee; Arunnehru Gopal; Young Kwan Sung; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Cells       Date:  2020-04-01       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.